Female participants at the 12mg dose achieved an average weight loss of 25.3 percent at 48 weeks
Not for human or animal use
WeightWatchers acquired Sequence, a GLP-1 telehealth business, for over $100 million in 2023, but the companys stock has been crushed across the same period as it has struggled to convert pre-Ozempic dieters into GLP-1 customers
Supplier Commitment Sourcing standards and batch-level quality commitment.
TRIUMPH-1 is the flagship obesity trial, targeting adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea
Results will likely be slower and less dramatic than injectable protocols, but meaningful improvement remains possible